US4758592A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating or preventing endometriosis
Assignee: Efamol Ltd
•
Filing: 1986-09-26
•
Granted: 1988-07-19
•
Expires: 2006-09-26
Abstract
Abstract Method of prevention or treatment of endometriosis wherein effective amounts of one or both of (i) gamma-linolenic acid and/or dihomo-gamma-linolenic acid and (ii) 18:4 n-3 and/or one or more of the metabolites of 18:4 n-3 (20:4 n-3, 20:5 n-3, 22:5 n-3 or 22:6 n-3) are administered against endometriosis as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto, alone or in an acceptable pharmaceutical carrier or diluent.
Inventors
- 👤 David F. Horrobin
- 👤 Robert A. Casper
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:52
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/16; A61K31/185; A61K31/19; A61K31/20; A61K31/21; A61K31/215; A61K31/22; A61K31/23; A61P; A61P43/00
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
76 words
A method of preventing or treating endometriosis comprising administering to a woman in need thereof effective amounts of one or both of i) gamma-linolenic acid, dihomo-gamma-linolenic acid or both or ii) stearidonic acid or one or more of the metabolites of stearidonic acid (delta-8,11,14,17- eicosatetraenoic acid, delta-5,8,11,14,17-eicosatetraenoic acid, delta-7,10,13,16,19-docosahexaenoic acid or delta-4,7,10,13,16,19-docosahexaenoic acid) as such or in the form of a pharmaceutically acceptable ester, salt, or amide, alone or in an acceptable pharmaceutical carrier or diluent.
Claim 2
Independent Claim
76 words
A method of preventing or treating endometriosis comprising administering to a woman in need thereof effective amounts of one or both of i) gamma-linolenic acid, dihomo-gamma-linolenic acid or both or ii) stearidonic acid or one or more of the metabolites of stearidonic acid (delta-8,11,14,17- eicosatetraenoic acid, delta-5,8,11,14,17-eicosatetraenoic acid, delta-7,10,13,16,19-docosahexaenoic acid or delta-4,7,10,13,16,19-docosahexaenoic acid) as such or in the form of a pharmaceutically acceptable ester, salt, or amide, alone or in an acceptable pharmaceutical carrier or diluent.
Claim 3
Dependent Claim
26 words
A method as claimed in claim 1 wherein the amounts of each said acid are 1 mg to 100 g, or submultiples thereof, per unit dose.
Claim 4
Dependent Claim
22 words
A method as claimed in claim 1 wherein the amounts of each said acid are 50 mg to 5 g per day.
References Cited (Backward Citations)
US4526902A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-07-19 | 1992-01-18 | 1992-07-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-07-19 | 1996-01-18 | 1996-07-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-07-19 | 2000-01-18 | 2000-07-19 | $7700.00 | Window Closed / Lapsed |